

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>GOLDMAN SACHS & CO. LLC</u> (Last) (First) (Middle) 200 WEST STREET (Street) NEW YORK NY 10282 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>T2 Biosystems, Inc. [TTOO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/24/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	03/24/2020		P		500	A	\$0.378	4,196,956 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	03/24/2020		S		500	D	\$0.378	4,196,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	03/25/2020		P		600	A	\$0.9279	4,197,056 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	03/25/2020		S		600	D	\$0.9279	4,196,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	04/09/2020		P		1,000	A	\$0.49	4,197,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	04/09/2020		S		1,000	D	\$0.49	4,196,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		2,655	D	\$0.52	4,193,801 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		1,000	D	\$0.521	4,192,801 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		1,000	D	\$0.526	4,191,801 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		500	D	\$0.528	4,191,301 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		50	D	\$0.53	4,191,251 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		500	D	\$0.5318	4,190,751 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		100	D	\$0.5325	4,190,651 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		6,256	D	\$0.54	4,184,395 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		100	D	\$0.55	4,184,295 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		939	D	\$0.5503	4,183,356 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		P		26,200	A	\$0.5517	4,209,556 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		10,100	D	\$0.57	4,199,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		2,000	D	\$0.5701	4,197,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		1,000	D	\$0.5702	4,196,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/12/2020		P		2,500	A	\$0.546	4,198,956 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/12/2020		S		2,500	D	\$0.546	4,196,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		200	D	\$0.8314	4,196,256 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		3,235	D	\$0.8318	4,193,021 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		2,031	D	\$0.8325	4,190,990 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		2,031	D	\$0.8326	4,188,959 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		P		10,328	A	\$0.8329	4,199,287 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		800	D	\$0.8345	4,198,487 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		2,031	D	\$0.8347	4,196,456 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock ⁽¹⁾⁽²⁾⁽³⁾	05/20/2020		P		5,126	A	\$0.803	4,201,582 ⁽⁴⁾⁽⁵⁾	I	See Footnotes ⁽⁴⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

1. Name and Address of Reporting Person*

[GOLDMAN SACHS & CO. LLC](#)

(Last) (First) (Middle)

200 WEST STREET

(Street)

NEW YORK NY 10282

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[GOLDMAN SACHS GROUP INC](#)

(Last) (First) (Middle)

200 WEST STREET

(Street)

NEW YORK NY 10282

(City) (State) (Zip)

Explanation of Responses:

1. These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.

2. Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934

(the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.

3. This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs (together, with GS Group, the "Reporting Persons"). Goldman Sachs is a subsidiary of GS Group.

4. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.

5. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Remarks:

Balance of trades included in attached schedule. (See Exhibit 99.1)

/s/ Jamison Yardley, Attorney- 08/03/2021
in-fact

/s/ Jamison Yardley, Attorney- 08/03/2021
in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Table 1 – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/ Day/ Year)	2A. Deemed Execution Date, if any (Month/ Day/ Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code (P) or (S)	V	Amount	(A) or (D)	Price			
Common Stock(1) (2)(3)	05/20/2020		S		5,820	D	\$ 0.8034	4,195,762(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/20/2020		P		694	A	\$ 0.8060	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		P		5,642	A	\$ 0.7900	4,202,098(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		S		13,800	D	\$ 0.7974	4,188,298(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		P		7,458	A	\$ 0.8000	4,195,756(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		P		1,950	A	\$ 0.8300	4,197,706(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		S		1,250	D	\$ 0.8300	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/28/2020		P		1,250	A	\$ 0.8500	4,197,706(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/28/2020		S		1,250	D	\$ 0.8500	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P		1,781	A	\$ 1.0700	4,198,237(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P		200	A	\$ 1.0900	4,198,437(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P		1,051	A	\$ 1.1000	4,199,488(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		S		10,000	D	\$ 1.1314	4,189,488(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P		4,835	A	\$ 1.1500	4,194,323(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P		2,133	A	\$ 1.1600	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/04/2020		P		7,500	A	\$ 1.2900	4,203,956(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/04/2020		S		7,500	D	\$ 1.2900	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/08/2020		P		3,200	A	\$ 1.3400	4,199,656(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/08/2020		S		5,474	D	\$ 1.3442	4,194,182(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/08/2020		P		2,274	A	\$ 1.3500	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		S		200	D	\$ 1.2900	4,196,256(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		P		38,963	A	\$ 1.3629	4,235,219(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		S		38,963	D	\$ 1.3629	4,196,256(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		P		3,800	A	\$ 1.3633	4,200,056(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		S		3,600	D	\$ 1.3674	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/10/2020		P		163,073	A	\$ 1.7000	4,359,529(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/10/2020		S		163,073	D	\$ 1.7000	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/10/2020		P		163,073	A	\$ 1.7317	4,359,529(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/10/2020		S		163,073	D	\$ 1.7317	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		S		2,000	D	\$ 1.5000	4,194,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		P		2,000	A	\$ 1.5300	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		S		2,000	D	\$ 1.5300	4,194,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		S		300	D	\$ 1.5800	4,194,156(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		P		46,050	A	\$ 1.5955	4,240,206(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		S		43,750	D	\$ 1.6000	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/15/2020		P		47,750	A	\$ 1.6100	4,234,206(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/15/2020		S		47,750	D	\$ 1.6100	4,186,456(4)(5)	I	See Footnotes(4) (5)

Common Stock(1)(2)(3)	06/16/2020	P	2,000	A	\$ 1.5000	4,188,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/16/2020	S	2,000	D	\$ 1.5000	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/17/2020	S	708	D	\$ 1.4410	4,185,748(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/17/2020	P	2,708	A	\$ 1.4476	4,188,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/17/2020	S	2,000	D	\$ 1.4500	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/29/2020	P	300	A	\$ 1.2900	4,186,756(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/29/2020	S	300	D	\$ 1.2900	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/29/2020	P	3,973	A	\$ 1.3300	4,190,429(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/29/2020	S	5,000	D	\$ 1.3341	4,185,429(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	06/29/2020	P	1,027	A	\$ 1.3500	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/01/2020	P	250,000	A	\$ 1.7542	4,436,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/01/2020	S	250,000	D	\$ 1.7542	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/01/2020	P	47,586	A	\$ 1.9254	4,234,042(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/01/2020	P	250,000	D	\$ 1.9362	4,484,042(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/01/2020	S	297,586	A	\$ 1.9345	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/07/2020	P	350	A	\$ 1.2400	4,186,806(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/07/2020	S	350	D	\$ 1.2400	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/08/2020	S	50	D	\$ 1.2900	4,186,406(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/08/2020	P	350	A	\$ 1.2943	4,186,756(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/08/2020	S	300	D	\$ 1.2950	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/21/2020	P	500	A	\$ 1.7400	4,267,807(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/21/2020	S	500	D	\$ 1.7400	4,267,307(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/22/2020	P	1,500	A	\$ 1.6813	4,187,956(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/22/2020	S	1,500	D	\$ 1.6813	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/23/2020	P	3,000	A	\$ 1.6883	4,189,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/23/2020	S	3,000	D	\$ 1.6883	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/24/2020	P	7,500	A	\$ 1.5500	4,193,956(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/24/2020	S	8,211	D	\$ 1.5508	4,185,745(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/24/2020	P	100	A	\$ 1.5550	4,185,845(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/24/2020	P	611	A	\$ 1.5600	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/28/2020	P	7,523	A	\$ 1.4800	4,193,979(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	07/28/2020	S	7,523	D	\$ 1.4800	4,186,456(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	08/03/2020	P	46,565	A	\$ 1.6473	4,233,021(4)(5)	I	See Footnotes(4)(5)
Common Stock(1)(2)(3)	08/03/2020	S	46,565	D	\$ 1.6473	4,186,456(4)(5)	I	See Footnotes(4)(5)

Explanation of Responses:

- These transactions in the common stock (the “Common Stock”) of T2 Biosystems, Inc. (the “Issuer”) have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC (“Goldman Sachs”) acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.
- Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
- This statement is being filed by The Goldman Sachs Group, Inc. (“GS Group”) and Goldman Sachs (together, with GS Group, the “Reporting Persons”). Goldman Sachs is a subsidiary of GS Group.
- GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the “GS Funds”) because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.

5. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.